Business Wire

Car Connectivity Consortium Releases Inaugural Industry Report on Global Vehicle Connectivity Trends

5.11.2025 16:00:00 EET | Business Wire | Press release

Share

The Car Connectivity Consortium® (CCC), the trusted source for defining how vehicles interact with devices and the world to enhance the consumer experience through standardized, secure, and convenient connectivity solutions, today released its 2025 Future of Vehicle Connectivity Report. The findings reveal how automakers, suppliers, and technology providers across regions are aligning around secure, seamless connectivity as a foundation for innovation.

With Deloitte projecting the value of software-defined vehicles to reach up to $600 billion by 2030, the connected vehicle market is entering a new phase of growth. To better understand how the industry is preparing for this evolution, the CCC surveyed its membership to uncover where companies are investing and focusing their attention. CCC’s more than 300 member companies include leading automakers, Tier 1 suppliers, smart device makers, and technology providers representing every major region. The survey, which gathered insights from over 250 respondents across 20+ countries, highlights privacy, ease of use, and interoperability as top priorities for connected vehicles.

“Our mission has always been to unify how vehicles and devices work together – securely and without friction,” said Alysia Johnson, President of the CCC. “This survey not only validates where the industry is headed but reinforces why CCC’s work to develop global technology standards and foster collaboration across automakers, suppliers, and technology providers is more critical than ever.”

Key Findings from the 2025 Future of Vehicle Connectivity Report:

  • Security and Ease of Use Are Top Consumer Priorities: 60% of CCC members ranked privacy/security and ease of use as the leading benefits for vehicle connectivity.
  • Fleet Management and Tracking Drive Innovation: 72% of respondents say GPS fleet tracking delivers strong value, while 62% cite fleet management – including rentals and rideshares – as a key growth area.
  • Connectivity Investments Deliver Positive ROI: More than half of fleet operators report a positive ROI within one year from predictive analytics and asset tracking.
  • Interoperability Technologies Gain Momentum: 82% of respondents said connected car and vehicle access are top priorities. Members also identified the technologies enabling that future – 84% cited Bluetooth® low energy (LE), 77% ultra-wideband (UWB), and 75% Near-Field Communication (NFC) – as critical to advancing secure, seamless connectivity.

“The data highlights how the connected vehicle industry is moving from promise to progress,” said Ian Televik, Marketing Director at the CCC. “Security and simplicity are now table stakes, and interoperability is the bridge connecting it all. CCC delivers that interoperability by developing global standards and a certification program that ensure connected experiences work reliably across brands and devices.”

Find more information on the Car Connectivity Consortium and download the 2025 Future of Vehicle Connectivity Report here.

About the Car Connectivity Consortium:

The Car Connectivity Consortium® (CCC) is a cross-industry organization dedicated to defining how vehicles interact with devices and the world to create a more seamless and secure consumer experience. CCC standardizes the connected ecosystem around vehicles and devices, bringing together automakers, device manufacturers, automotive suppliers, chip vendors, and security providers to develop solutions that prioritize convenience, security, and privacy protections. With more than 300 member companies, CCC plays a leading role in advancing smartphone-to-vehicle connectivity and shaping the future of trusted digital vehicle access. Its Board of Directors includes representatives from Apple, BMW, CARIAD, DENSO, Ford, General Motors, Google, Honda, Hyundai, Mercedes-Benz, NXP, Panasonic Automotive Systems, Samsung, Thales, and Xiaomi. For more information, visit www.carconnectivity.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105030158/en/

Contacts

Media Contact
Ally Hodapp
INK Communications for CCC
ccc@ink-co.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye